健康元(600380.SH)：创新药研发方面已在呼吸、抗感染等核心领域布局超20款1类创新药

Core Viewpoint - The company has laid out over 20 first-class innovative drugs in key areas such as respiratory and anti-infection, indicating a strong focus on innovative drug development [1] Group 1: Innovative Drug Development - The company is advancing its innovative drug pipeline with a focus on respiratory and anti-infection fields [1] - The first-class innovative drug, Marpatsavir capsules, targeting influenza, is in the late review stage and is expected to be launched soon, with a pediatric formulation entering phase III clinical trials [1] - Multiple innovative drugs, including TSLP monoclonal antibodies and PREP inhibitors for chronic obstructive pulmonary disease (COPD), are steadily progressing through clinical trials [1] Group 2: Future Focus - The company will continue to concentrate on core innovative drug development, aiming for product layout and technological breakthroughs with a global perspective [1]